Daniel
Former Novartis chief stays on company payroll
A bonanza payout to the former chairman of Novartis has been cut back radically, the pharmaceutical group said on Wednesday, reporting also a fall in second quarter profit.
A bonanza payout to the former chairman of Novartis has been cut back radically, the pharmaceutical group said on Wednesday, reporting also a fall in second quarter profit.